The controversy surrounding the skinny label hinges on its legal implications, with generics being permitted to market using labels that exclude patented indications, fundamentally altering patent protections in pharmaceuticals.
Hikma's appeal against Amarin raises critical questions about the boundaries of patent law in the pharmaceutical industry, particularly how the skinny label permits widespread generic use despite existing method patents.
Collection
[
|
...
]